All In Biotech

Drug Trial Radar · NCT03866525

OH2 Oncolytic Viral Therapy in Solid Tumors

Phase I/II Study of OH2 Injection, an Oncolytic Type 2 Herpes Simplex Virus Expressing Granulocyte Macrophage Colony-Stimulating Factor, in Malignant Solid Tumors

Last checked: Nov 19, 2026Latest source record: Dec 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Apr 2, 2019

Primary completion

Aug 30, 2025

Study completion Aug 30, 2025

Sponsor

Sponsor type
Industry
First posted
Mar 7, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I/II study evaluates the safety and efficacy of OH2 as single agent or in combination with HX008, an anti-PD-1 antibody, in patients with malignant solid tumors (gastrointestinal cancers, head and neck cancers, soft tissue sarcomas). OH2 is an oncolytic virus developed upon genetic modifications of the herpes simplex virus type 2 strain HG52, allowing the virus to selectively replicate in tumors. Meanwhile, the delivery of the gene encoding human granulocyte macrophage colony-stimulating factor (GM-CSF) may induce a more potent antitumor immune response.

Conditions

  • Solid Tumor
  • Gastrointestinal Cancer

Interventions

  • OH2 injection, with or without irinotecan or HX008Biological

    OH2: Oncolytic Type 2 Herpes Simplex Virus Irinotecan: cytotoxic agent HX008: anti-PD-1 antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The dose-limiting toxicities (DLTs) of OH2 injection as single agent and in combination with HX008 in patients with solid tumorsTime frame: 6 months
  2. The maximum-tolerated doses (MTDs) of OH2 injection as single agent and in combination with HX008 in patients with solid tumorsTime frame: 6 months
  3. The biodistribution and biologic effect of OH2 injectionTime frame: 6 months
  4. The anti-tumor activity of OH2 monotherapy and in combination with irinotecan or HX008Time frame: 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.